Literature DB >> 14531770

Chronic kidney disease and cardiovascular disease in the Medicare population.

Allan J Collins1, Shuling Li, David T Gilbertson, Jiannong Liu, Shu-Cheng Chen, Charles A Herzog.   

Abstract

BACKGROUND: The extent of diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD) in the Medicare population is relatively unknown. Also unknown is the effect of these diseases on patient survival before end-stage renal disease (ESRD).
METHODS: Prevalent cohorts of Medicare enrollees from 1996 to 2000 were assessed for diabetes and CKD, presence of CVD, and probability of death versus ESRD in the follow-up period. Hospitalization rates and, in diabetics, lipid testing and glycemic control monitoring were also assessed.
RESULTS: The prevalence of diabetes in the Medicare population increased at 4.4% per year, reaching 18.9% in the 1999-2000 cohort. Approximately 726,000 elderly Medicare enrollees carry a diagnosis code for CKD. Those with CKD are 5 to 10 times more likely to die before reaching ESRD than the non-CKD group. In CKD patients, CVD is twice as common and advances at twice the rate. Cardiovascular disease advances at a similarly higher rate in CKD patients who die and those who survive to ESRD. Heart failure hospitalizations are 5 times greater in CKD patients and only 30% less than those in dialysis patients. Only half of the CKD patients with diabetes who advance to ESRD had a lipid or glycosylated hemoglobin test done in the year before or after dialysis initiation.
CONCLUSION: Diabetes, the leading cause of ESRD, is increasing in the general Medicare population at 4.4% per year. Cardiovascular disease is common, progresses at twice the rate, is associated with death before ESRD, and patients receive suboptimal risk factor monitoring. Active identification and treatment of CKD patients is needed.

Entities:  

Mesh:

Year:  2003        PMID: 14531770     DOI: 10.1046/j.1523-1755.64.s87.5.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  84 in total

1.  Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention.

Authors:  Elias B Hanna; Anita Y Chen; Matthew T Roe; Stephen D Wiviott; Caroline S Fox; Jorge F Saucedo
Journal:  JACC Cardiovasc Interv       Date:  2011-09       Impact factor: 11.195

2.  Increased cardiovascular risk associated with reduced kidney function.

Authors:  Timothy P Ryan; Susan G Fisher; Jessica L Elder; Paul C Winters; William Beckett; James Tacci; James A Sloand
Journal:  Am J Nephrol       Date:  2009-01-19       Impact factor: 3.754

Review 3.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

4.  [Cardiovascular disease, renal disease and other chronic diseases. Earlier intervention is needed in chronic renal disease].

Authors:  Ángel Luis Martín de Francisco; Luis Aguilera García; Valentí Fuster Carulla
Journal:  Aten Primaria       Date:  2009-07-24       Impact factor: 1.137

5.  Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system.

Authors:  Stephen F Derose; Mark P Rutkowski; Peter W Crooks; Jiaxiao M Shi; Jean Q Wang; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Nathan W Levin; Steven J Jacobsen
Journal:  Am J Kidney Dis       Date:  2013-03-15       Impact factor: 8.860

6.  Geographic variation in CKD prevalence and ESRD incidence in the United States: results from the reasons for geographic and racial differences in stroke (REGARDS) study.

Authors:  Rikki M Tanner; Orlando M Gutiérrez; Suzanne Judd; William McClellan; C Barrett Bowling; Brian D Bradbury; Monika M Safford; Mary Cushman; David Warnock; Paul Muntner
Journal:  Am J Kidney Dis       Date:  2012-12-08       Impact factor: 8.860

7.  Aortic PWV in chronic kidney disease: a CRIC ancillary study.

Authors:  Raymond R Townsend; Neil J Wimmer; Julio A Chirinos; Afshin Parsa; Matthew Weir; Kalyani Perumal; James P Lash; Jing Chen; Susan P Steigerwalt; John Flack; Alan S Go; Mohammed Rafey; Mahboob Rahman; Angela Sheridan; Crystal A Gadegbeku; Nancy A Robinson; Marshall Joffe
Journal:  Am J Hypertens       Date:  2009-12-17       Impact factor: 2.689

Review 8.  Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.

Authors:  RenJie Lu; Yan Zhang; Xishan Zhu; Zhengda Fan; Shanmei Zhu; Manman Cui; Yanping Zhang; Fenglei Tang
Journal:  Int Urol Nephrol       Date:  2016-05-18       Impact factor: 2.370

9.  Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample.

Authors:  Wolfgang Lieb; Ralf A Benndorf; Emelia J Benjamin; Lisa M Sullivan; Renke Maas; Vanessa Xanthakis; Edzard Schwedhelm; Jayashri Aragam; Friedrich Schulze; Rainer H Böger; Ramachandran S Vasan
Journal:  Atherosclerosis       Date:  2008-08-28       Impact factor: 5.162

10.  Adherence to a healthy lifestyle and all-cause mortality in CKD.

Authors:  Ana C Ricardo; Magdalena Madero; Wei Yang; Cheryl Anderson; Matthew Menezes; Michael J Fischer; Mary Turyk; Martha L Daviglus; James P Lash
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.